Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis

Journal of Experimental Medicine

Volumn 209, Issue 12, 2012, Pages 2149-2156

  Kim, Jungsu ^a   Eltorai, Adam E M ^a   Jiang, Hong ^a   Liao, Fan ^a   Verghese, Philip B ^a   Kim, Jaekwang ^a   Stewart, Floy R ^a   Basak, Jacob M ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; HJ6.3 ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; IMMUNIZATION; IMMUNOTHERAPY; MALE; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; TREATMENT RESPONSE;

AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; ANIMALS; ANTIBODIES, MONOCLONAL; APOLIPOPROTEINS E; BRAIN DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IMMUNOTHERAPY; MALE; MICE; MICE, TRANSGENIC; STATISTICS, NONPARAMETRIC;

EID: 84871887566     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20121274     Document Type: Article

References (25)

1. Bard, F., C. Cannon, R. Barbour, R.L. Burke, D. Games, H. Grajeda, T.Guido, K. Hu, J. Huang, K. Johnson-Wood, et al. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:916-919. http://dx.doi.org/10.1038/78682
2. Bien-Ly, N., A.K. Gillespie, D. Walker, S.Y. Yoon, and Y. Huang. 2012. Reducing human apolipoprotein E levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic mice. J. Neurosci. 32:4803-4811. http://dx.doi.org/10.1523/JNEUROSCI.0033-12.2012
3. Brody, D.L., and D.M. Holtzman. 2008. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci. 31:175-193. http://dx.doi.org/10.1146/annurev.neuro.31.060407.125529
4. Castano, E.M., F. Prelli, T. Wisniewski, A. Golabek, R.A. Kumar, C. Soto, and B. Frangione. 1995. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem. J. 306:599-604.
5. Castellano, J.M., J. Kim, F.R. Stewart, H. Jiang, R.B. DeMattos, B.W. Patterson, A.M. Fagan, J.C. Morris, K.G. Mawuenyega, C. Cruchaga, et al. 2011. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 3:89ra57. http://dx.doi.org/10.1126/scitranslmed.3002156
6. Deane, R., A. Sagare, K. Hamm, M. Parisi, S. Lane, M.B. Finn, D.M. Holtzman, and B.V. Zlokovic. 2008. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118:4002-4013. http://dx.doi.org/10.1172/JCI36663
7. DeMattos, R.B., J.R. Cirrito, M. Parsadanian, P.C. May, M.A. O'Dell, J.W. Taylor, J.A. Harmony, B.J. Aronow, K.R. Bales, S.M. Paul, and D.M. Holtzman. 2004. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 41:193-202. http://dx.doi.org/10.1016/S0896-6273(03)00850-X
8. Golde, T.E., P. Das, and Y. Levites. 2009. Quantitative and mechanistic studies of Abeta immunotherapy. CNS Neurol. Disord. Drug Targets. 8:31-49. http://dx.doi.org/10.2174/187152709787601830
9. Golde, T.E., L.S. Schneider, and E.H. Koo. 2011. Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron. 69:203-213. http://dx.doi.org/10.1016/j.neuron.2011.01.002
10. Holtzman, D.M., J.C. Morris, and A.M. Goate. 2011. Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 3:sr1.
11. Jankowsky, J.L., D.J. Fadale, J. Anderson, G.M. Xu, V. Gonzales, N.A. Jenkins, N.G. Copeland, M.K. Lee, L.H. Younkin, S.L. Wagner, et al.2004. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13:159-170. http://dx.doi.org/10.1093/hmg/ddh019
12. Jiang, Q., C.Y. Lee, S. Mandrekar, B. Wilkinson, P. Cramer, N. Zelcer, K. Mann, B. Lamb, T.M. Willson, J.L. Collins, et al. 2008. ApoE promotes the proteolytic degradation of Abeta. Neuron. 58:681-693. http://dx.doi.org/10.1016/j.neuron.2008.04.010
13. Kim, J., J.M. Basak, and D.M. Holtzman. 2009a. The role of apolipo-protein E in Alzheimer's disease. Neuron. 63:287-303. http://dx.doi.org/10.1016/j.neuron.2009.06.026
14. Kim, J., J.M. Castellano, H. Jiang, J.M. Basak, M. Parsadanian, V. Pham, S.M. Mason, S.M. Paul, and D.M. Holtzman. 2009b. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 64:632-644. http://dx.doi.org/10.1016/j.neuron.2009.11.013
15. Kim, J., H. Jiang, S. Park, A.E. Eltorai, F.R. Stewart, H. Yoon, J.M. Basak, M.B. Finn, and D.M. Holtzman. 2011. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J. Neurosci. 31:18007-18012. http://dx.doi .org/10.1523/JNEUROSCI.3773-11.2011
16. Koenigsknecht-Talboo, J., M. Meyer-Luehmann, M. Parsadanian, M. Garcia-Alloza, M.B. Finn, B.T. Hyman, B.J. Bacskai, and D.M. Holtzman. 2008. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J. Neurosci. 28:14156-14164. http://dx.doi.org/10.1523/JNEUROSCI.4147-08.2008
17. Lucin, K.M., and T. Wyss-Coray. 2009. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron. 64:110-122. http://dx.doi.org/10.1016/j.neuron.2009.08.039
18. Ma, J., A. Yee, H.B. Brewer Jr., S. Das, and H. Potter. 1994. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 372:92-94. http://dx.doi.org/10.1038/372092a0
19. Namba, Y., M. Tomonaga, H. Kawasaki, E. Otomo, and K. Ikeda. 1991. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541:163-166. http://dx.doi.org/10.1016/0006-8993(91)91092-F
20. Sadowski, M.J., J. Pankiewicz, H. Scholtzova, P.D. Mehta, F. Prelli, D. Quartermain, and T. Wisniewski. 2006. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 103:18787-18792. http://dx.doi.org/10.1073/pnas.0604011103
21. Santuccione, A.C., M. Merlini, A. Shetty, C. Tackenberg, J. Bali, M.T. Ferretti, J. McAfoose, L. Kulic, C. Bernreuther, T. Welt, et al. 2012. Active vaccination with ankyrin G reduces β-amyloid pathology in APP transgenicmice. Mol. Psychiatry.
22. Wang, A., P. Das, R.C. Switzer III, T.E. Golde, and J.L. Jankowsky. 2011. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-β immunotherapy. J. Neurosci. 31:4124-4136. http://dx.doi.org/10.1523/JNEUROSCI.5077-10.2011
23. Wilcock, D.M., S.K. Munireddy, A. Rosenthal, K.E. Ugen, M.N. Gordon, and D. Morgan. 2004. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol. Dis. 15:11-20. http://dx.doi.org/10.1016/j.nbd .2003.09.015
24. Wisniewski, T., and B. Frangione. 1992. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135:235-238. http://dx.doi.org/10.1016/0304-3940 (92)90444-C
25. Wisniewski, T., E.M. Castão, A. Golabek, T. Vogel, and B. Frangione. 1994. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145:1030-1035.